WO2019221215A1 - Composition médicinale particulaire contenant de la lubiprostone - Google Patents

Composition médicinale particulaire contenant de la lubiprostone Download PDF

Info

Publication number
WO2019221215A1
WO2019221215A1 PCT/JP2019/019433 JP2019019433W WO2019221215A1 WO 2019221215 A1 WO2019221215 A1 WO 2019221215A1 JP 2019019433 W JP2019019433 W JP 2019019433W WO 2019221215 A1 WO2019221215 A1 WO 2019221215A1
Authority
WO
WIPO (PCT)
Prior art keywords
rubiprostone
polymer compound
pharmaceutical composition
composition according
particulate pharmaceutical
Prior art date
Application number
PCT/JP2019/019433
Other languages
English (en)
Japanese (ja)
Inventor
圭祐 枝村
林田　知大
洋平 帆足
Original Assignee
ニプロ株式会社
全星薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニプロ株式会社, 全星薬品工業株式会社 filed Critical ニプロ株式会社
Priority to JP2020519907A priority Critical patent/JPWO2019221215A1/ja
Publication of WO2019221215A1 publication Critical patent/WO2019221215A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Definitions

  • rubiprostone and a polymer compound By making rubiprostone and a polymer compound into a solid dispersion, at least a part of rubiprostone is present in an amorphous form in the solid dispersion with the polymer compound.
  • the amorphous form of rubiprostone is inherently less stable than the crystalline form.
  • at least a part of rubiprostone is kept in an amorphous state and more stable than crystalline rubiprostone. Can be increased. In this way, a stable particulate pharmaceutical composition containing rubiprostone can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition médicinale particulaire contenant de la lubiprostone qui est facile à ingérer et pratique à manipuler et qui présente une stabilité et une uniformité de contenu exceptionnelles. La composition médicinale particulaire comprend une dispersion solide contenant : une lubiprostone ou un sel pharmaceutiquement acceptable d'une lubiprostone, ou une lubiprostone ou un hydrate d'un sel pharmaceutiquement acceptable d'une lubiprostone; et un composé de poids moléculaire élevé.
PCT/JP2019/019433 2018-05-18 2019-05-16 Composition médicinale particulaire contenant de la lubiprostone WO2019221215A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020519907A JPWO2019221215A1 (ja) 2018-05-18 2019-05-16 ルビプロストン含有粒子状医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018096201 2018-05-18
JP2018-096201 2018-05-18

Publications (1)

Publication Number Publication Date
WO2019221215A1 true WO2019221215A1 (fr) 2019-11-21

Family

ID=68539769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/019433 WO2019221215A1 (fr) 2018-05-18 2019-05-16 Composition médicinale particulaire contenant de la lubiprostone

Country Status (2)

Country Link
JP (1) JPWO2019221215A1 (fr)
WO (1) WO2019221215A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511445A (ja) * 1999-10-15 2003-03-25 スカンポ・アクチェンゲゼルシャフト 二環式化合物組成物およびその安定化方法
WO2009104205A1 (fr) * 2008-02-20 2009-08-27 Lupin Limited Formulation à libération retardée d’un activateur du canal chlorure
CN103550224A (zh) * 2013-11-13 2014-02-05 崔合芳 一种治疗便秘和/或痔疮的药物组合物及其用途
CN104667259A (zh) * 2015-03-26 2015-06-03 深圳市健元医药科技有限公司 治疗慢性便秘的药物组合物胶囊及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008114859A1 (fr) * 2007-03-22 2008-09-25 Astellas Pharma Inc. Composition pharmaceutique contenant un dérivé de pyrazole
WO2018065826A1 (fr) * 2016-10-06 2018-04-12 Sucampo Ag Billes multicouches à usage pharmaceutique
CN108186597A (zh) * 2016-12-08 2018-06-22 北大方正集团有限公司 一种鲁比前列酮固体分散体及其制备方法
CN107854435B (zh) * 2016-12-15 2019-01-22 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
JP2020536880A (ja) * 2017-10-06 2020-12-17 エイジネックス・ホンコン・イノヴェイティヴ・リミテッドＡｔｈｅｎｅｘ Ｈｋ Ｉｎｎｏｖａｔｉｖｅ Ｌｉｍｉｔｅｄ 高強度経口タキサン組成物及び方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511445A (ja) * 1999-10-15 2003-03-25 スカンポ・アクチェンゲゼルシャフト 二環式化合物組成物およびその安定化方法
WO2009104205A1 (fr) * 2008-02-20 2009-08-27 Lupin Limited Formulation à libération retardée d’un activateur du canal chlorure
CN103550224A (zh) * 2013-11-13 2014-02-05 崔合芳 一种治疗便秘和/或痔疮的药物组合物及其用途
CN104667259A (zh) * 2015-03-26 2015-06-03 深圳市健元医药科技有限公司 治疗慢性便秘的药物组合物胶囊及其制备方法

Also Published As

Publication number Publication date
JPWO2019221215A1 (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
KR101665395B1 (ko) 6-플루오로-3-히드록시-2-피라진카르복사미드 함유 정제 및 조립분말
JP5296456B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP4446177B2 (ja) 耐湿性口腔内崩壊錠の製造方法
JPWO2002024166A1 (ja) 崩壊性が良好な経口製剤
JP5490347B2 (ja) 経口投与用製剤
WO2016136849A1 (fr) Préparation solide
JP2017141299A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
ES2901598T3 (es) Comprimido recubierto con película que tiene una alta estabilidad química del ingrediente activo
JP5318400B2 (ja) レボフロキサシン含有錠剤
JP7336388B2 (ja) 錠剤及びその製造方法
JP2013216701A (ja) 経口投与用製剤
JP2016050206A (ja) レボカルニチンを含有する医薬錠剤
JP5275815B2 (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
JP5978335B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2020111089A1 (fr) Composition pharmaceutique
JP6538321B2 (ja) 経口組成物
WO2019221215A1 (fr) Composition médicinale particulaire contenant de la lubiprostone
JP6151413B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2009269858A (ja) サルポグレラート経口投与製剤
WO2020122244A1 (fr) Comprimé, et procédé de fabrication de celui-ci
US9775832B2 (en) Pharmaceutical composition for oral administration
JP5714652B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
KR20180098282A (ko) 압축 성형 제제
JP2017119632A (ja) 経口固形組成物
TW201609193A (zh) 含有碳酸鹽之口腔內崩解錠劑用組成物及口腔內崩解錠劑

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19802646

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020519907

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19802646

Country of ref document: EP

Kind code of ref document: A1